Tyra Biosciences (TYRA) Competitors

Tyra Biosciences logo
$19.57 -0.17 (-0.86%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$19.59 +0.02 (+0.10%)
As of 03:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TYRA vs. IONS, DNTH, TVTX, CRSP, and LEGN

Should you buy Tyra Biosciences stock or one of its competitors? Tyra Biosciences's main competitors and comparable companies include Ionis Pharmaceuticals (IONS), Dianthus Therapeutics (DNTH), Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), and Legend Biotech (LEGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tyra Biosciences compare to Ionis Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tyra Biosciences has a net margin of 0.00% compared to Ionis Pharmaceuticals' net margin of -56.98%. Tyra Biosciences' return on equity of -40.12% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals-56.98% -120.62% -16.99%
Tyra Biosciences N/A -40.12%-37.62%

Ionis Pharmaceuticals currently has a consensus price target of $75.71, indicating a potential upside of 180.84%. Tyra Biosciences has a consensus price target of $47.40, indicating a potential upside of 142.21%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.78
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Tyra Biosciences. MarketBeat recorded 26 mentions for Ionis Pharmaceuticals and 22 mentions for Tyra Biosciences. Ionis Pharmaceuticals' average media sentiment score of 0.22 beat Tyra Biosciences' score of -0.20 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ionis Pharmaceuticals
6 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
6 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Ionis Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Tyra Biosciences has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ionis Pharmaceuticals$944M4.76-$381.39M-$3.32N/A
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A

Summary

Tyra Biosciences beats Ionis Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Tyra Biosciences compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Dianthus Therapeutics presently has a consensus target price of $128.77, suggesting a potential upside of 48.04%. Tyra Biosciences has a consensus target price of $47.40, suggesting a potential upside of 142.21%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Dianthus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dianthus Therapeutics
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
3.00
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

In the previous week, Tyra Biosciences had 6 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 22 mentions for Tyra Biosciences and 16 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.51 beat Tyra Biosciences' score of -0.20 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dianthus Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Dianthus Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Tyra Biosciences has lower revenue, but higher earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dianthus Therapeutics$2.04M2,400.90-$162.34M-$3.99N/A
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A

Tyra Biosciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -7,436.50%. Dianthus Therapeutics' return on equity of -19.68% beat Tyra Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Dianthus Therapeutics-7,436.50% -19.68% -18.95%
Tyra Biosciences N/A -40.12%-37.62%

47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Dianthus Therapeutics and Tyra Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Travere Therapeutics?

Travere Therapeutics (NASDAQ:TVTX) and Tyra Biosciences (NASDAQ:TYRA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Travere Therapeutics has higher revenue and earnings than Tyra Biosciences. Travere Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Travere Therapeutics$490.73M10.00-$25.55M-$1.29N/A
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A

In the previous week, Tyra Biosciences had 19 more articles in the media than Travere Therapeutics. MarketBeat recorded 22 mentions for Tyra Biosciences and 3 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.32 beat Tyra Biosciences' score of -0.20 indicating that Travere Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Travere Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

84.1% of Tyra Biosciences shares are held by institutional investors. 4.4% of Travere Therapeutics shares are held by company insiders. Comparatively, 12.5% of Tyra Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Travere Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market. Comparatively, Tyra Biosciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

Travere Therapeutics presently has a consensus target price of $72.55, suggesting a potential upside of 41.97%. Tyra Biosciences has a consensus target price of $47.40, suggesting a potential upside of 142.21%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Travere Therapeutics
2 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.69
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93

Tyra Biosciences has a net margin of 0.00% compared to Travere Therapeutics' net margin of -18.66%. Tyra Biosciences' return on equity of -40.12% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Travere Therapeutics-18.66% -185.69% -17.24%
Tyra Biosciences N/A -40.12%-37.62%

Summary

Tyra Biosciences beats Travere Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to CRISPR Therapeutics?

Tyra Biosciences (NASDAQ:TYRA) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Tyra Biosciences has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Tyra Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tyra BiosciencesN/A -40.12% -37.62%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

Tyra Biosciences has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A
CRISPR Therapeutics$3.51M1,109.56-$581.60M-$4.74N/A

In the previous week, Tyra Biosciences had 13 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 22 mentions for Tyra Biosciences and 9 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.32 beat Tyra Biosciences' score of -0.20 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral
CRISPR Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

84.1% of Tyra Biosciences shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 12.5% of Tyra Biosciences shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tyra Biosciences has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Tyra Biosciences presently has a consensus price target of $47.40, indicating a potential upside of 142.21%. CRISPR Therapeutics has a consensus price target of $72.93, indicating a potential upside of 81.64%. Given Tyra Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Tyra Biosciences is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

Summary

Tyra Biosciences beats CRISPR Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Tyra Biosciences compare to Legend Biotech?

Tyra Biosciences (NASDAQ:TYRA) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

In the previous week, Legend Biotech had 5 more articles in the media than Tyra Biosciences. MarketBeat recorded 27 mentions for Legend Biotech and 22 mentions for Tyra Biosciences. Legend Biotech's average media sentiment score of -0.12 beat Tyra Biosciences' score of -0.20 indicating that Legend Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tyra Biosciences
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral
Legend Biotech
1 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
10 Negative mention(s)
1 Very Negative mention(s)
Neutral

Tyra Biosciences has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Tyra Biosciences has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tyra BiosciencesN/AN/A-$119.95M-$2.64N/A
Legend Biotech$1.03B3.04-$296.80M-$0.01N/A

84.1% of Tyra Biosciences shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 12.5% of Tyra Biosciences shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tyra Biosciences has a net margin of 0.00% compared to Legend Biotech's net margin of -0.02%. Legend Biotech's return on equity of -0.03% beat Tyra Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Tyra BiosciencesN/A -40.12% -37.62%
Legend Biotech -0.02%-0.03%-0.02%

Tyra Biosciences currently has a consensus target price of $47.40, suggesting a potential upside of 142.21%. Legend Biotech has a consensus target price of $48.64, suggesting a potential upside of 201.94%. Given Legend Biotech's higher probable upside, analysts clearly believe Legend Biotech is more favorable than Tyra Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tyra Biosciences
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
2.93
Legend Biotech
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Tyra Biosciences beats Legend Biotech on 8 of the 15 factors compared between the two stocks.

Get Tyra Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TYRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TYRA vs. The Competition

MetricTyra BiosciencesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.36B$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.6634.2628.24
Price / SalesN/A15.788.485.70
Price / CashN/A22.9521.0121.90
Price / Book1.954.184.463.72
Net Income-$119.95M-$24.15M$3.52B$393.10M
7 Day Performance-6.68%-7.78%-5.92%-5.76%
1 Month Performance5.67%-5.96%-4.58%-7.14%
1 Year Performance22.01%-8.08%-1.93%-7.46%

Tyra Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TYRA
Tyra Biosciences
2.4403 of 5 stars
$19.57
-0.9%
$47.40
+142.2%
+23.1%$1.36BN/AN/A87
IONS
Ionis Pharmaceuticals
3.5505 of 5 stars
$27.77
-10.4%
$78.00
+180.9%
-63.2%$5.15B$944MN/A1,402
DNTH
Dianthus Therapeutics
2.233 of 5 stars
$88.81
-1.3%
$128.77
+45.0%
+110.4%$5.07B$2.04MN/A92
TVTX
Travere Therapeutics
3.6952 of 5 stars
$51.99
+0.7%
$72.55
+39.5%
+44.2%$4.96B$490.73MN/A497
CRSP
CRISPR Therapeutics
2.6387 of 5 stars
$45.15
-9.8%
$69.69
+54.3%
-27.4%$4.85B$3.51MN/A393

Related Companies and Tools


This page (NASDAQ:TYRA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners